DNMT3A and acute myeloid leukemia: In the R/R AML cohort, in patients with adverse ELN risk and DNMT3A mutation, the FLT3mut group exhibited an inferior response (CRc) than the FLT3wt group (OR, 0.3; 95% CI: 0.1–1.0; p = 0.043; OR, 0.2; 95% CI: 0.1–0.7; p = 0.016; Figure S1B, respectively).